Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M49,028Revenue $M5,770Net Margin (%)6.2Z-Score1.8
Enterprise Value $M64,605EPS $-2.7Operating Margin %20.2F-Score7
P/E(ttm))103Cash Flow Per Share $4.9Pre-tax Margin (%)5.3Higher ROA y-yY
Price/Book9.810-y EBITDA Growth Rate %2.9Quick Ratio1.1Cash flow > EarningsY
Price/Sales6.45-y EBITDA Growth Rate %41.4Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %163ROA % (ttm)1.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)9.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M336ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 146.0623%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 146.0623%Add 12.4%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 146.0623%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 146.0623%Add 8.89%10,985,940
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 146.0623%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 146.0623%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 146.0623%Add 0.57%34,494,015
VRXAndreas Halvorsen 2014-09-30 Reduce-1.02%$106.73 - $130.26
($118.9)
$ 146.0623%Reduce -15.75%9,967,690
VRXLee Ainslie 2014-09-30 Reduce-0.18%$106.73 - $130.26
($118.9)
$ 146.0623%Reduce -3.7%2,527,896
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 146.0623%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 146.0614%Add 8.19%6,050,442
VRXAndreas Halvorsen 2014-06-30 Add1.39%$116.99 - $138.13
($127.6)
$ 146.0614%Add 27.27%11,830,932
VRXSteve Mandel 2014-06-30 Add0.64%$116.99 - $138.13
($127.6)
$ 146.0614%Add 14.44%10,089,450
VRXLee Ainslie 2014-06-30 Add0.37%$116.99 - $138.13
($127.6)
$ 146.0614%Add 8.39%2,625,014
VRXGeorge Soros 2014-06-30 Add0.29%$116.99 - $138.13
($127.6)
$ 146.0614%Add 185.46%472,187
VRXChris Davis 2014-06-30 Add0.17%$116.99 - $138.13
($127.6)
$ 146.0614%Add 16.03%3,153,748
VRXJoel Greenblatt 2014-06-30 Buy 0.01%$116.99 - $138.13
($127.6)
$ 146.0614%New holding, 6172 sh.6,172
VRXDaniel Loeb 2014-06-30 Sold Out -0.48%$116.99 - $138.13
($127.6)
$ 146.0614%Sold Out0
VRXJohn Paulson 2014-06-30 Reduce-0.32%$116.99 - $138.13
($127.6)
$ 146.0614%Reduce -49.97%500,300
VRXWallace Weitz 2014-06-30 Reduce-0.19%$116.99 - $138.13
($127.6)
$ 146.0614%Reduce -2.91%1,551,076
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRX George Soros 2014-09-30626,7480.190.61+32.73%
VRX Lou Simpson 2014-09-301,815,9160.549.2+12.4%
VRX Chris Davis 2014-09-303,529,2371.051.4+11.91%
VRX Wallace Weitz 2014-09-301,691,5250.56.5+9.05%
VRX Steve Mandel 2014-09-3010,985,9403.275.6+8.89%
VRX Glenn Greenberg 2014-09-306,586,5821.9632+8.86%
VRX John Paulson 2014-09-30520,7000.160.28+4.08%
VRX Ruane Cunniff 2014-09-3034,494,01510.2824+0.57%
VRX Jeff Ubben 2014-09-3018,923,8775.6416.6
VRX Private Capital 2014-09-30296,8710.094.6-1.19%
VRX Jean-Marie Eveillard 2014-09-301,010,8020.30.33-1.33%
VRX Lee Ainslie 2014-09-302,527,8960.754.8-3.7%
VRX Andreas Halvorsen 2014-09-309,967,6902.975.3-15.75%
VRX Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.48-8.99view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.064.28view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.730.23view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.730.23view
Farmer, RonDirector 2014-11-24Buy1,000$163.95-10.91view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.95-10.91view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.252.68view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.720.02view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.720.02view
Mirovsky, PavelSenior Officer 2014-06-02Sell10,000$131.2511.28view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 
    Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectiv Nov 14 2014 
    Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
    Valeant Part XIII: channeling Jeff Skilling - or trying to reconstruct Valeant's balance sheet Oct 30 2014 
    Wallace Weitz's Partners Value Fund Q3 2014 Commentary Oct 16 2014 
    Ackman's Pershing Square Now Available To The Public Oct 13 2014 
    Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
    Wallace Weitz's Value Fund Q2 Commentary Oct 06 2014 
    Transcript of Ruane, Cunniff & Goldfarb Investor Day - May 16, 2014 Oct 05 2014 
    Most Held Canadian Stocks of the Second Quarter Sep 04 2014 

    More From Our Partners
    Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog Dec 18 2014 - ZACKS

    More From Other Websites
    Business Highlights Dec 19 2014
    Ackman Accused of Insider Trading in Allergan Shareholder Suit Dec 18 2014
    9 Big Stocks That Doubled in 2014 Dec 18 2014
    Great Stocks: Valeant Pharmaceuticals Near Buy Point Dec 16 2014
    Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
    Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
    Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Dec 15 2014
    Nestlé Chief Paul Bulcke Takes a Global View Dec 13 2014
    Shire Updates on Pipeline at Research & Development Day Dec 11 2014
    JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Dec 10 2014
    Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan Dec 10 2014
    Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Dec 09 2014
    UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 Dec 09 2014
    Where Could ValueAct Capital's New $1.5 Billion Go? Dec 09 2014
    Stock Market Today: Wall Street Drops; Conn's Down 40% Dec 09 2014
    Valeant puts dealmaking on hold to focus on the bottom line Dec 09 2014
    Will Valeant Pharmaceuticals (VRX) Stock be Helped Today by New Strategy? Dec 09 2014
    December 9 Premarket Briefing: 10 Things You Should Know Dec 09 2014
    Two Gauges That Point To Fund Buying In A Stock Dec 08 2014
    Novartis (NVS) Presents Additional Data on Leukemia Drug Dec 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK